Digital Ischemia and Necrosis from Oxaliplatin

Oxaliplatin is a chemotherapeutic agent used in a variety of malignancies such as colorectal cancer and pancreatic cancer. It is a platinum derivative that results in direct cell cytotoxicity with resultant cell death. The most common side effects often noted are neurotoxicity, nausea, vomiting, diarrhea, hepatotoxicity and myelosuppression. Oxaliplatin induced digital ischemia and necrosis is a rare side effect that was observed in our patient. In general, digital ischemia is a rare vascular disorder that is often associated with autoimmune disease [1]. Here, we intend to present a patient with digital ischemia due to Oxaliplatin, which was a chemotherapy agent used in the treatment of his urachal adenocarcinoma.

Download Full-text

Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting

RSC Advances ◽

10.1039/d1ra01093j ◽

2021 ◽

Vol 11 (26) ◽

pp. 16131-16141

Author(s):

Manali Haniti Mohd-Zahid ◽

Siti Nadiah Zulkifli ◽

Che Azurahanim Che Abdullah ◽

JitKang Lim ◽

Sharida Fakurazi ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Gold Nanoparticles ◽

Cancer Cells ◽

Cancer Cell ◽

Chemotherapeutic Agent ◽

Cell Targeting ◽

Specific Targeting ◽

Colorectal Cancer Cells ◽

Cancer Cell Targeting

5-FU-PEGylated AuNPs-CD133 is designed to improve specific targeting of 5-FU against colorectal cancer cells which abundantly express CD133.

Download Full-text

Norepinephrine transporter analog benzylguanidine-conjugated nanoparticles for the delivery of paclitaxel in neuroblastoma

Nanomedicine ◽

10.2217/nnm-2021-0230 ◽

2021 ◽

Author(s):

Ozlem Ozen Karakus ◽

Kavitha Godugu ◽

Taher Salaheldin ◽

Kazutoshi Fujioka ◽

Shaker A Mousa

Keyword(s):

Polyethylene Glycol ◽

Targeted Delivery ◽

Chemotherapeutic Agent ◽

Norepinephrine Transporter ◽

Neuroendocrine Cells ◽

Safe Delivery ◽

Targeted Nanoparticles ◽

Chemotherapy Agent ◽

Neuroblastoma Tumor ◽

Targeted Agent

Aim: We previously synthesized a polyethylene glycol-based norepinephrine transporter-targeted agent, BG-P-TAT, which has a benzylguanidine and a triazolyl-tetrac group. This targeted conjugate showed suppression of neuroblastoma tumor progression. In this study we aimed to synthesize nanoparticles to encapsulate the chemotherapeutic agent paclitaxel for targeting neuroblastoma tumors by using benzylguanidine so that it can compete with norepinephrine for uptake by neuroendocrine cells. Methods: Biocompatible poly(lactide-co-glycolic acid)-polyethylene glycol was chosen to prepare targeted nanoparticles for safe delivery of the chemotherapy agent paclitaxel. Result: Paclitaxel concentration was 60% higher in neuroblastoma tumors of mice treated with paclitaxel encapsulated in targeted nanoparticles than with non-targeted nanoparticles. Conclusion: These findings support the targeted delivery of paclitaxel as a chemotherapeutic agent for neuroblastoma.

Download Full-text

5-FLUOROURACIL INDUCED HEART FAILURE: RECOGNIZING A RARE SIDE EFFECT IN A COMMON CHEMOTHERAPEUTIC AGENT

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(19)33216-4 ◽

2019 ◽

Vol 73 (9) ◽

pp. 2610

Author(s):

Maitreyee Rai ◽

Meghana Parsi ◽

Jonathan Finkel

Keyword(s):

Heart Failure ◽

Side Effect ◽

Chemotherapeutic Agent ◽

Rare Side Effect

Download Full-text

Blepharitis: a rare side effect related to cetuximab in patient with colorectal cancer

BMJ Case Reports ◽

10.1136/bcr-2019-231774 ◽

2019 ◽

Vol 12 (8) ◽

pp. e231774 ◽

Cited By ~ 1

Author(s):

Sukesh Manthri ◽

Kanishka Chakraborty

Keyword(s):

Colorectal Cancer ◽

Side Effect ◽

Rare Side Effect

Download Full-text

Abstract 692: Antitumor activity of novel structure-based chemotherapeutic agent for the intervention of colorectal cancer

10.1158/1538-7445.am10-692 ◽

2010 ◽

Author(s):

Aruna S. Jaiswal ◽

Sanjeev Banerjee ◽

Harekrushna Panda ◽

Charles D. Bulkin ◽

Tadahide Izumi ◽

...

Keyword(s):

Colorectal Cancer ◽

Antitumor Activity ◽

Chemotherapeutic Agent ◽

Novel Structure

Download Full-text

Abstract 3004: Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with nintedanib on human colorectal cancer xenografts

10.1158/1538-7445.am2016-3004 ◽

2016 ◽

Author(s):

Norihiko Suzuki ◽

Fumio Nakagawa ◽

Mamoru Nukatsuka ◽

Kazuaki Matsuoka ◽

Hiroshi Tsukihara ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Chemotherapy ◽

Chemotherapeutic Agent ◽

Human Colorectal Cancer

Download Full-text

Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype

JCO Precision Oncology ◽

10.1200/po.17.00027 ◽

2017 ◽

pp. 1-12 ◽

Cited By ~ 8

Author(s):

Jordan Kardos ◽

Sara E. Wobker ◽

Michael E. Woods ◽

Matthew E. Nielsen ◽

Angela B. Smith ◽

...

Keyword(s):

Colorectal Cancer ◽

Immune Checkpoint ◽

Transcriptome Profiling ◽

Immune Checkpoint Blockade ◽

Checkpoint Blockade ◽

Rna Expression ◽

Precision Oncology ◽

Rare Type ◽

Msh6 Mutation ◽

Urachal Adenocarcinoma

Purpose Urachal adenocarcinoma is a rare type of primary bladder adenocarcinoma that comprises less than 1% of all bladder cancers. The low incidence of urachal adenocarcinomas does not allow for an evidence-based approach to therapy. Transcriptome profiling of urachal adenocarcinomas has not been previously reported. We hypothesized that an in-depth molecular understanding of urachal adenocarcinoma would uncover rational therapeutic strategies. Patients and Methods We performed targeted exon sequencing and global transcriptome profiling of 12 urachal tumors to generate a comprehensive molecular portrait of urachal adenocarcinoma. A single patient with an MSH6 mutation was treated with the anti–programmed death-ligand 1 antibody, atezolizumab. Results Urachal adenocarcinoma closely resembles colorectal cancer at the level of RNA expression, which extends previous observations that urachal tumors harbor genomic alterations that are found in colorectal adenocarcinoma. A subset of tumors was found to have alterations in genes that are associated with microsatellite instability ( MSH2 and MSH6) and hypermutation ( POLE). A patient with an MSH6 mutation was treated with immune checkpoint blockade, which resulted in stable disease. Conclusion Because clinical trials are next to impossible for patients with rare tumors, precision oncology may be an important adjunct for treatment decisions. Our findings demonstrate that urachal adenocarcinomas molecularly resemble colorectal adenocarcinomas at the level of RNA expression, are the first report, to our knowledge, of MSH2 and MSH6 mutations in this disease, and support the consideration of immune checkpoint blockade as a rational therapeutic treatment of this exceedingly rare tumor.

Download Full-text